Plain-English translation of NCT06191120 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new type of imaging scan called [18F]-ALF-FAPI-74 PET/CT to identify a specific subtype of colorectal cancer (called CMS4) that tends to be more aggressive and may respond differently to treatment. The imaging scan works by using a special tracer that highlights certain features of cancer cells. Researchers hope this scan will help doctors identify which patients have this aggressive subtype so they can consider different treatment approaches.
About 25% of colorectal cancer patients have this aggressive CMS4 subtype, which has a worse outlook and may not respond as well to standard chemotherapy. Currently, doctors have no reliable way to identify this cancer type before surgery, so all patients receive the same treatment regardless of their cancer subtype. This imaging scan could help doctors personalize treatment by identifying which patients need different therapy options.
You likely qualify if…
You likely don't qualify if…
You will undergo one or two imaging scans (called [18F]-ALF-FAPI-74 PET/CT scans) before your planned liver surgery, depending on your specific situation and whether you receive chemotherapy before surgery. The imaging scan is similar to standard PET scans and takes a couple of hours. Your cancer tissue that is removed during your surgery will be analyzed to see if the imaging scan accurately identified your cancer subtype, helping researchers understand if this new scan could be useful for future patients.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
Netherlands